On Monday,
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) announced that that it plans to conduct an interim data review of its re-purposed drug NP-120 (Ifenprodil) Phase 2b/3 COVID-19 multi-national human study. The Company will look at the primary endpoint of the World Health Organization (WHO) ordinal score and also secondary endpoints including the number of days that patients were in the intensive care unit and the hospital, as well as the number of days patients were on mechanical ventilation, and oxygen.
Algernon Pharmaceuticals’ Chief Executive Officer, Christopher J. Moreau commented that with the quickly increasing global threat from COVID-19, the Company believes that they have an obligation to find out now how its COVID-19 trial is trending.
“If Ifenprodil has been performing well in the study, this early look at the data may allow us to accelerate our COVID-19 program accordingly.”
To find out the latest on this trial,
click here.
The clinical stage pharmaceutical development Company recently stated that and after its second meeting and review, the external Data and Safety Monitoring Board (DSMB) had unanimously approved the continuation of the Company’s multinational Phase 2b/3 human study of Ifenprodil for the treatment of COVID-19. The DSMB is a committee of clinical research experts, including physicians, statisticians, and patient advocates, who are monitoring the progress of the Company’s clinical trial, and are reviewing safety and effectiveness data while the trial is ongoing.
CEO Moreau noted that clinical studies are focussed on the issues of safety and efficacy.
“We are very confident of Ifenprodil’s safety and we look forward to discovering its efficacy in this very important COVID-19 trial.”
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.